<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662077</url>
  </required_header>
  <id_info>
    <org_study_id>VIH-IBAN</org_study_id>
    <nct_id>NCT00662077</nct_id>
  </id_info>
  <brief_title>Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort</brief_title>
  <official_title>Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project wills to determine the incidence of osteoporosis in our population of&#xD;
      HIV-infected patients and to assess the efficacy and security of ibandronate, whose efficacy&#xD;
      in post-menopausal women has already been proved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The lower bone mineral density that has been described in patients with HIV-infection has not&#xD;
      meant an increase of long term complications. Nevertheless, it could involve an increase if&#xD;
      the associated co-mordibity in the future, taking in care that in general population&#xD;
      osteoporosis increases 4 times the pathologic fracture risk. That's why it is necessary to&#xD;
      know the real prevalence of osteoporosis in this population of patients so the real&#xD;
      dimensions of the problems can be defined.&#xD;
&#xD;
      This project wills to determine the incidence of osteoporosis in our population of&#xD;
      HIV-infected patients and to assess the efficacy and security of ibandronate, whose efficacy&#xD;
      in post-menopausal women has been already proved. If the quarterly use of endovenous&#xD;
      ibandronate obtains equivalent results to those obtained with oral and weekly alendronate in&#xD;
      other studies with the same population, its use would be justified because of its posology&#xD;
      benefits. The monthly or quarterly administration can improve compliance in patients who are&#xD;
      recieving a big quantity of drugs, as HIV infected patients do and who probably have to be&#xD;
      treated for life. Moreover, its elimination is renal so there is absence of interactions with&#xD;
      antiretroviral drugs what mades of ibandronate a very promising alternative. Finally, there's&#xD;
      no risk of digestive intolerance because of its parenteral administration and it has a better&#xD;
      posology than oral bifosfonates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Financial difficulties&#xD;
  </why_stopped>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in lumbar (L2-4) and femoral (trochanter, femur neck, total femur and hip) t-score bone mineral density</measure>
    <time_frame>BL, W24, W48, W72, W96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>BL, W12, W24, W36, W48, W60, W72, W80, W96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab tests</measure>
    <time_frame>BL, W12, W24, W36, W48, W60, W72, W80, W96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related clinical events (bone fractures)</measure>
    <time_frame>BL, W12, W24, W36, W48, W60, W72, W80, W96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoblastic/Osteoclastic activity, bone formation/reabsorption.</measure>
    <time_frame>BL, W12, W24, W36, W48, W60, W72, W80, W96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibandronate + Lifestyle modifications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lifestyle modifications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>Ibandronate endovenous 3 mg every 3 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modifications</intervention_name>
    <description>Lifestyle modifications: counseling every 3 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old or elder.&#xD;
&#xD;
          2. Documented HIV-1 infection, with or without antiretroviral treatment.&#xD;
&#xD;
          3. Presence of WHO osteoporosis criteria, defined as t-score under -2.5 in lumbar, hip&#xD;
             and/or trochanter. (DEXA in the last 6 months is needed)&#xD;
&#xD;
          4. Willing to follow the study protocol.&#xD;
&#xD;
          5. Informed Consent signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In women, pregnancy or breastfeeding.&#xD;
&#xD;
          2. Other possible causes of secondary osteoporosis.&#xD;
&#xD;
          3. Creatinin over 2.3mg/mL&#xD;
&#xD;
          4. Glomerular filter less than 50 mL/min (estimated through MDRD)&#xD;
&#xD;
          5. Alendronate treatment in the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenia Negredo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital - Lluita Sida Foundation</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Dra. EUGENIA NEGREDO PUIGMAL</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>bifosfonates</keyword>
  <keyword>ibandronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

